Selective PKA Inhibitor Compounds for Aberrant Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatment options are inadequate for diseases associated with constitutive activation of Protein Kinase A (PKA) signaling, such as cancer, due to the lack of effective inhibitors for PRKACA and PRKACB kinase inhibitors.
Innovation Solution
Development of novel substituted pyrrolo[2,3-b]pyridin-4-yl benzamide compounds that act as selective inhibitors of the PKA catalytic subunits PRKACA and/or PRKACB, which can be used to treat diseases characterized by aberrant PKA signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatment options are used for diseases associated with constitutive activation of PKA signaling, then treatment coverage is limited, but the lack of effective PRKACA and PRKACB kinase inhibitors results in inadequate therapeutic outcomes
Solution Approach 1:
The patent employs parameter changes by developing compounds with specific molecular structures (substituted pyrrolo[2,3-b]pyridin-4-yl benzamides) that optimize binding affinity to PKA catalytic subunits. By varying substituent groups (R1, R2, X, Y parameters in Formula I) and their configurations, the invention achieves different levels of inhibition potency and selectivity for PRKACA and PRKACB, thereby improving therapeutic effectiveness while maintaining broad applicability across multiple disease types
Solution Approach 2:
The patent segments the PKA enzyme into its regulatory subunits and catalytic subunits (PRKACA and PRKACB), and develops inhibitors that specifically target the catalytic subunits. This segmentation approach allows the invention to address constitutive activation at the precise molecular level by blocking the catalytic activity of PRKACA and/or PRKACB without affecting other kinases, thereby achieving both high therapeutic effectiveness and broad treatment coverage across multiple PKA-driven diseases
2Reliability
If selective inhibitors of PRKACA and/or PRKACB are developed, then therapeutic effectiveness for PKA-mediated diseases is improved, but the complexity of identifying and optimizing selective compounds increases
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups at defined positions (R1 at position 1, R2 at position 2, X and Y at positions 3 and 4 of the pyrrolo[2,3-b]pyridine ring) of the benzamide core structure. Each substituent is carefully selected to provide local interactions with specific residues in the PKA catalytic subunit binding pocket, thereby achieving high selectivity for PRKACA and/or PRKACB over other kinases while simplifying the optimization process through systematic structure-activity relationship analysis
Solution Approach 2:
The patent employs composite material principles by combining the pyrrolo[2,3-b]pyridin-4-yl benzamide core structure with various substituent groups (including but not limited to aryl, heteroaryl, alkyl, and functional groups) to create a library of compounds with differentiated selectivity profiles. This composite approach allows systematic optimization of selectivity for PRKACA and/or PRKACB by combining different structural modules, thereby managing complexity through modular design rather than random screening
3Adaptability or versatility
If compounds with broad PKA inhibition are developed, then treatment coverage for multiple diseases is expanded, but the risk of off-target effects and side effects increases
Solution Approach 1:
The patent applies dynamics by designing compounds that can differentially inhibit PRKACA and/or PRKACB based on disease-specific requirements. The substituted pyrrolo[2,3-b]pyridin-4-yl benzamide structure allows for dynamic modulation of inhibition profiles through substituent variation, enabling the same core compound to be optimized for specific disease indications while maintaining selectivity, thereby expanding treatment coverage without proportionally increasing off-target effects
Data Source
AI summary
Described herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof and solvates of any of the foregoing capable of inhibiting protein kinase A and/or its mutants, pharmaceutical compositions comprising at least one of the compounds, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, processes for making the compounds, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, and methods of using the same.